Pain medicine has long confronted a seemingly unavoidable pharmacologic bargain: the drugs most capable of relieving severe pain could also produce euphoria, physical dependence, respiratory depression, and, in vulnerable individuals, addiction.
Much of America's response to the opioid crisis has focused on controlling exposure to these drugs through prescription monitoring, stricter prescribing guidelines, and dose thresholds. While well-intended, the fundamental question remains: Is the problem the opioid receptor itself, or where in the body we activate it?
That question points to one of the most interesting developments in recent analgesic pharmacology: opioid drugs designed to relieve pain in the peripheral nervous system while remaining largely outside the brain.
The innovation would not solve the opioid crisis, because most people who are harmed by opioids do not receive them from a provider for pain. But if the approach works—and the if is important—it could transform pain medicine.
An Idea Decades in the Making
The scientific foundation for this approach is not new. In a remarkable 1995 review in the New England Journal of Medicine, Christoph Stein demonstrated that receptors on peripheral sensory nerves can inhibit pain before signals ever reach the central nervous system.
Stein reviewed experimental work showing that opioids could produce potent local pain relief in peripheral tissue without crossing the blood-brain barrier. This provided evidence that the analgesia was genuinely peripheral rather than the result of the drug reaching the brain. Crucially, Stein also pointed to human evidence: small doses of intra-articular morphine administered after knee surgery reduced postoperative pain, sometimes for prolonged periods. The effects could be reversed by naloxone, confirming an opioid-receptor mechanism.
Stein presciently observed that peripherally acting opioids might herald a new approach to pain management, providing analgesia without central adverse effects such as sedation, respiratory depression, dysphoria, nausea, or addiction. He also acknowledged it remained unknown whether tolerance would eventually develop.
That was 1995. Three decades later, advances in medicinal chemistry may finally be making it possible to test the theory in clinical trials.
Keep the Analgesia—Keep the Drug Out of the Brain
Traditional opioids like morphine, oxycodone, hydrocodone, and fentanyl readily enter the central nervous system, where they activate receptors involved in pain relief, reward, sedation, and respiratory control. The peripheral-opioid strategy challenges the assumption that these effects must come as a package deal.
Rather than abandoning opioid pharmacology altogether, researchers could design molecules that activate opioid receptors outside the brain with minimal central nervous system penetration. The concept is elegantly simple: If pain can be attenuated at peripheral receptors, perhaps the brain does not need to be exposed to the drug at all.
A Case Study in Peripheral Targeting
One orally bioavailable compound attempting to exploit this approach is DMX-101 [Figure 1], currently under development by DIMERx. DMX-101 is a covalently linked buprenorphine dimer designed to preferentially target peripheral opioid receptors while limiting central nervous system exposure. It acts as a partial mu-opioid agonist and full kappa-opioid antagonist without entering the brain.
Early findings in more than 400 subjects across Phase 1 and Phase 2 studies report mild-to-moderate adverse events without the typical central opioid effects. These findings are preliminary until independently evaluated in specific indications. Preclinical studies also suggest analgesic activity in inflammatory and neuropathic pain models without evidence of meaningful central nervous system activity.
Even more notably, at the 2026 College on Problems of Drug Dependence annual meeting, investigators reported results from a rodent self-administration experiment. Animals trained to self-administer hydrocodone continued doing so when given the chance, but when DMX-101 was substituted, self-administration behavior declined over successive sessions. Even at exposures substantially exceeding anticipated human therapeutic doses, the drug failed to produce reinforcing behavior.
An animal study does not prove a drug is non-addictive in humans, nor does it rule out physical dependence, tolerance, withdrawal, or other opioid-related adverse effects. But as a proof of concept, showing that a molecule derived from opioid pharmacology does not trigger central reward pathways is a critical milestone.
Rethinking How We Treat Pain
For the last decade, American policy has treated reducing opioid exposure as a primary metric of success. But prescribing less medication and treating pain effectively are not synonymous. Clinicians still encounter patients with severe pain for whom existing non-central therapies are insufficient or inappropriate.
An effective analgesic that treats severe pain without exposing the brain to euphoria and respiratory depression would change that equation. "Opioid" describes activity at a family of receptors; it does not mean every molecule interacting with those receptors must behave like oxycodone or fentanyl. A drug such as DMX-101 could potentially reduce one source of opioid exposure, allowing treatment of serious pain without unnecessary exposure to centrally acting opioids.
Remaining Questions
Several critical questions remain before this strategy can enter routine clinical practice:
- Clinical Efficacy: Does peripheral targeting deliver clinically meaningful analgesia in human trials?
- Human Abuse Potential: Will human abuse-liability testing reflect the low reinforcement seen in animal models?
- Long-term Effects: How do tolerance, physical dependence, and side-effect profiles evolve with prolonged use—a key question Stein highlighted 30 years ago?
- High-Dose Safety Margins: Does limiting central penetration prevent clinically important respiratory depression and central toxicity even at supratherapeutic doses?
A New Angle on an Old Problem
For years, the national conversation has asked how pain medicine can use fewer opioids. A better scientific question may be: can we preserve what opioids do well while eliminating what makes them dangerous?
Christoph Stein posed the biological foundation for that possibility three decades ago. Modern medicinal chemistry is now allowing researchers to test it in ways that were difficult to imagine then.
Most experimental drugs fail during development, and claims regarding abuse potential require rigorous evidence. But the underlying concept deserves serious attention. The next breakthrough in pain medicine may not be eliminating opioid pharmacology entirely but learning how to harness peripheral receptors without forcing the brain to pay the price.
Lynn Webster (he/him), M.D., is an addiction and pain specialist. He is a Senior Fellow at the Center for U.S. Policy and co-author of Deconstructing Toxic Narratives: Data, Disparities and a New Path Forward in the Opioid Crisis (Springer Nature 2026).
Lynn Webster, MD
Lynn R. Webster, MD, is a pain and addiction medicine specialist and serves as Executive Vice President of Scientific Affairs at Dr. Vince Clinical Research, where he consults with pharmaceutical companies.
